Australia's CSL half-year profit up despite weak flu vaccine sales
Australian biopharmaceutical company CSL posted higher first-half profits as growth in its main blood-plasma business helped offset weaker flu vaccine sales, which were hit by "significantly" low ...
Victorian farm tests positive for bird flu as egg shortages continue
Consumers are still facing egg shortages and price rises as the ramifications of Australia's largest bird flu outbreak ...
Falling US flu vaccine rates hurt Australia's CSL profit growth
The Behring unit, which makes up around 70% of CSL's revenue, recorded a 15% jump in immunoglobulin sales to $3.17 billion, ...
The Land13h
Everyone has a role to play in biosecurity
ExoFlare has developed a smart biosecurity system for producers that enables them to identify and control biosecurity ...
CSL revenues take a hit as US citizens turn away from vaccination
CSL’s vaccine division is suffering as Americans turn away from flu vaccinations, with a “very severe” influenza season ...
CSL says on track for double-digit growth but vaccine sales weak
The ASX-listed pharmaceutical giant has shrugged off a sluggish period and says it expects profits to rise by more than 10 ...
SA supermarket egg shortages hit again amid new Victoria bird flu outbreak
A new highly virulent strain of bird flu that could have “devastating impacts on South Australia’s poultry industry” has been ...
CSL lifts HY profit as plasma sales jump, offsets flu vaccine weakness
Investing.com-- Australian biopharmaceutical giant CSL Ltd (ASX: CSL) reported a rise in half-year net profit, driven ...
PharmiWeb19h
ENA Respiratory Receives US$5m Investment from Flu…
ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defence immune enhancers to minimize the impact of viral respiratory infections, announces today it has received a ...